【摘要】 目的探讨Fas、FasL和B细胞淋巴瘤因子2(Bcl-2)蛋白在非小细胞肺癌组织的表达及临床意义。方法用免疫组化EnVison法检测60例非小细胞肺癌组织Fas、FasL和Bcl-2蛋白的表达,并分析其与病理分期、肿瘤分化和淋巴结转移的关系。同时,取癌旁5cm以上正常肺组织18例作为对照。结果Fas、FasL和Bcl-2蛋白在非小细胞肺癌组织中的表达与癌旁肺组织相比差异有显著性(Hc=12.26～37.07,P<0.01)。Fas蛋白的表达与肿瘤TNM分期、分化程度及淋巴结转移相关(Hc=20.21、18.31,u=-3.38,P<0.01);FasL蛋白的表达也与肿瘤TNM分期、分化程度及淋巴结转移相关(Hc=15.09、8.61,u=-2.16,P<0.05);Bcl-2蛋白的表达与肿瘤TNM分期、分化程度及淋巴结转移相关(Hc=14.15、8.84,u=-3.03,P<0.01)。结论Fas、FasL及Bcl-2蛋白表达失衡与非小细胞肺癌的发生发展密切相关。更多还原

【Abstract】 Objective To explore the expressions of Fas,FasL and Bcl-2 in non-small cell lung cancer (NSLC) and their clinical significance. Methods EnVison immunohistochemical method was used to examine the expressions of Fas,FasL and Bcl-2 in 60 NSLC patients,the relationship between the expressions and pathologic staging,differentiation,and lymph node metastasis were analyzed. The normal tissue 5 cm away from the cancer was taken from 18 cases served as controls. Results The differences of expressions of Fas,FasL and Bcl-2 between cancer tisue and paraneoplastic were significant (Hc=12.26-37.07,P<0.01),their expressions were correlated with TNM staging,differentiation and lymphatic metastasis,respectively (Hc=20.21,18.31,u=-3.38,P<0.01;Hc=15.09,8.61,u=-2.16,P<0.05; and Hc=14.15,8.84,u=-3.03,P<0.01). ConclusionDisbalance of the expressions of Fas,FasL and Bcl-2 is closely associated with the occurrence and development of non-small cell lung cancer.更多还原